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Summary
To maintain bone mass turnover and bone mineral density
(BMD), bone marrow (BM) mesenchymal stem cells (MSCs) are
constantly recruited and subsequently differentiated into osteo-
blasts. HIV-infected patients present lower BMD than non-HIV
infected individuals and a higher prevalence of osteopenia/
osteoporosis. In antiretroviral treatment (ART)-naive patients,
encoded HIV proteins represent pathogenic candidates. They are
released by infected cells within BM and can impact on neigh-
bouring cells. In this study, we tested whether HIV proteins Tat
and/or Nef could induce senescence of human BM-MSCs and
reduce their capacity to differentiate into osteoblasts. When
compared to nontreated cells, MSCs chronically treated with Tat
and/or Nef up to 30 days reduced their proliferative activity and
underwent early senescence, associated with increased oxidative
stress and mitochondrial dysfunction. The antioxidant molecule
N-acetyl- cysteine had no or minimal effects on Tat- or Nef-
induced senescence. Tat but not Nef induced an early increase in
NF-jB activity and cytokine/chemokine secretion. Tat-induced
effects were prevented by the NF-jB inhibitor parthenolide,
indicating that Tat triggered senescence via NF-jB activation
leading to oxidative stress. Otherwise, Nef- but not Tat-treated
cells displayed early inhibition of autophagy. Rapamycin, an
autophagy inducer, reversed Nef-induced senescence and oxida-
tive stress. Moreover, Tat+Nef had cumulative effects. Finally, Tat
and/or Nef decreased the MSC potential of osteoblastic differen-
tiation. In conclusion, our in vitro data show that Tat and Nef
could reduce the number of available precursors by inducing MSC
senescence, through either enhanced inflammation or reduced
autophagy. These results offer new insights into the pathophys-
iological mechanisms of decreased BMD in HIV-infected patients.
Key words: HIV proteins; senescence; oxidative stress;
inflammation; autophagy; osteoblastic differentiation.
Introduction
Bone remodelling is controlled by the balance between osteoblast-
mediated bone deposition and osteoclast-mediated bone resorption.
Under pathophysiological conditions, this balance is affected and leads
to abnormal bone mass turnover and to bone loss. Mesenchymal stem
cells (MSCs) are multipotent precursors, with the capacity to differ-
entiate towards multiple tissue lineages such as adipocytes, chondro-
blasts and osteoblasts (Verma et al., 2002; Kim et al., 2012). To
achieve osteogenic differentiation and maintain bone mass, MSCs
within the bone marrow (BM) proceed through a number of functional
stages including proliferation, matrix maturation and mineralization.
Osteoporosis and osteopenia are bone disorders characterized by a
loss of bone mass and consequent reduction in bone strength, which
in turn leads to an increased risk of fractures (Mazziotti et al., 2010).
While a certain degree of bone weakening with age is considered
normal, several clinical studies have shown that HIV-infected patients
present an increased prevalence of osteopenia ranging from 20% to
50% and of osteoporosis reaching up to 20% (Powderly, 2002; Brown
& Qaqish, 2006; Stone et al., 2010). It is now clearly established that
HIV infection is an independent risk factor for osteopenia and
osteoporosis (Dolan et al., 2006; Stone et al., 2010). Cross-sectional
studies of ART-naive HIV-infected patients found altered levels of bone
turnover markers, in accordance with a reduced level of bone
formation when compared to HIV-uninfected controls (Haskelberg
et al., 2011).
Currently, HIV infection is controlled by efficient ART, transforming
this situation into a chronic disease. However, elderly HIV-infected
patients often present an increased incidence of age- related comor-
bidities, including significant reductions in bone mineral density (BMD).
These observations led to propose that HIV-infected patients suffer
from accentuated aging (Capeau, 2011). The increased risk of
osteoporosis in HIV-infected patients probably results from a combined
effect of ART and HIV infection, in addition to other classical risk
factors as drug consumption, low body weight and immune dysfunc-
tion (Stone et al., 2010; Castronuovo et al., 2013). To better under-
stand the pathophysiology of bone loss in these patients is an
important challenge.
Clinical studies have established that several HIV-related factors,
including HIV infection and chronic inflammation, affected the balance
between bone formation and resorption (Aukrust et al., 1999;
Haskelberg et al., 2011). As MSCs express the CD4 receptors and
CCR5 and CXCR4 coreceptors, it is conceivable that these cells are
susceptible to HIV infection, although integrated proviruses are rarely
found and a productive infection has not yet been documented
(Nazari-Shafti et al., 2011). Nonetheless, hematopoietic progenitor
cells (HPCs) in the BM of HIV-infected individuals have been proposed
as a persistent HIV reservoir (McNamara et al., 2013), releasing HIV
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proteins or infectious virions that could induce bystander harmful
effect on surroundings cells, such as apoptosis, oxidative stress,
mitochondrial dysfunctions or autophagy alterations (Kyei et al., 2009;
Raymond et al., 2011; Debaisieux et al., 2012). Proximity of MSCs and
infected HPCs in the BM niche makes MSCs a direct target of the HIV
proteins. Some HIV proteins such as gp120, Gag, Tat and Rev have
been shown to affect osteoblastic differentiation and activity in vitro
(Cotter et al., 2007, 2011; Gibellini et al., 2010).
Aging MSCs display reduced proliferative and osteoblastic
differentiation capacities (Fehrer & Lepperdinger, 2005; Zhou et al.,
2008), which contribute to decreased bone formation. Therefore, we
hypothesized that bystander effects of HIV proteins arising from
neighbouring infected cells or from reservoirs may abrogate marrow
MSC self-renewal by inducing early aging and affecting differentiation
properties. We chose to study two HIV proteins secreted by infected cells
in the extracellular medium: Tat (trans-activator of transcription), which
Fig. 1 Long-term exposure to Tat and/or Nef inhibits proliferation and induces senescence in mesenchymal stem cells (MSCs). The population doubling level (PDL) was
calculated as stated in Experimental procedures. Mean PDL values ( SEM) were determined at the indicated days post- HIV-protein treatment (A). The per cent inhibition of
population growth was calculated for each HIV protein by determining the increase in total cell number that occurred after 20 days of continuous exposure to HIV proteins,
compared to control cells (B). Cultures of nonconfluent MSCs on coverslips were fixed, stained with BrdU and analysed by immunofluorescence microscopy to determine the
number of dividing cells after day 10 and day 20 of HIV-protein treatment (C). Representative micrographs of BrdU positive cells and DAPI-stained cells at day 20 are shown
(D). The per cent of apoptotic cells was determined as stated in Experimental procedures (E). Senescence was evaluated by SA-b-galactosidase activity and expressed as the
total per cent of SA-b-galactosidase positive cells at pH6 (F). Representative micrographs of SA-b-galactosidase positive cells are shown (G). Lysosomal accumulation was
assessed by LysoTracker fluorescence probe and expressed as per cent of control cells (H). Whole-cell lysates, extracted from MSCs at day 10 and day 20 of HIV-proteins
treatment, were analysed by immunoblotting. Representative immunoblots of cell cycle arrest markers p21WAF1 and tubulin (loading control) are shown (I). Results are mean
 SEM. All experiments were performed in duplicate or triplicate in MSCs isolated from 3 to 4 different bone marrow donors. *P < 0.05, **P < 0.01,***P < 0.001, vs
control cells.
(A) (B)
(E)(D)
(C)
Fig. 2 Tat and/or Nef induce oxidative stress and mitochondrial dysfunction in MSCs. MSCs were treated with the HIV proteins Tat and/or Nef up to 20 days. ROS
production was assessed by the oxidation of CM-H2DCFDA (A) and the reduction of NBT (B) and expressed as % of control cells. Superoxide dismutase activity was evaluated
as stated in Experimental procedures and expressed as per cent of control cells (C). Mitochondrial mass was evaluated by MitoTracker Red-Probe, and results are expressed as
per cent of control cells (D). The cationic dye JC-1 evaluates mitochondrial membrane potential, monomers (green fluorescence) and aggregates (red–orange fluorescence)
were quantified. The results are expressed as the ratio of aggregate/monomer fluorescence (E). Results are mean  SEM. All experiments were performed in duplicate or
triplicate. *P < 0.05, **P < 0.01,***P < 0.001, vs control cells.
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is essential for transcriptional activation and able to recruit and activate
NF-jB (nuclear factor j-light-chain-enhancer of activated B cells) (Fiume
et al., 2012; Ju et al., 2012), and Nef (negative-regulating factor), an
accessory protein protecting HIV from degradation by acting as an
anti-autophagic maturation factor (Dinkins et al., 2010; Raymond et al.,
2011). We tested whether Tat and/or Nef could induce premature
senescence of osteoblast precursor stem cells, namely MSCs, which in
turn could be involved in osteoblast depletion and bone loss.
(A) (B)
(C) (D)
(F)(E)
(G)
Fig. 3 NAC treatment prevents oxidative
stress and partially prevents Tat-induced
senescence in MSCs. NAC was added, or
not, at day 10, for 10 days. ROS production
was assessed on day 20 post-HIV-protein
treatment by the oxidation of CM-
H2DCFDA (A) and the reduction of NBT (B).
Mitochondrial mass was evaluated by
MitoTracker Red-Probe (C), and
mitochondrial membrane potential by JC-1
fluorescent dye (D). Mean cell number and
the per centinhibition of population growth
were calculated for each condition (E).
Senescence was evaluated by SA-b-
galactosidase activity and expressed as the
total per cent of SA-b-galactosidase cells at
pH6 (F). Lysosomal accumulation was
assessed by LysoTracker fluorescence probe
and expressed as Per cent of control cells
(G). Results are mean  SEM. All
experiments were performed in duplicate or
triplicate. *P < 0.05, **P < 0.01,
***P < 0.001, vs control or vs Tat- and/or
Nef-treated cells without NAC. NS,
nonsignificant.
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Results
Long term treatment with Tat and/or Nef inhibits
proliferation and induces senescence of MSCs
We first evaluated whether chronic exposure for 20 days to Tat and/or
Nef affected the proliferation capacities of MSCs in vitro. Human MSCs
treated with Tat and/or Nef displayed a reduced proliferative activity that
worsened with increasing cellular passages (Fig. 1A). Population dou-
bling level (PDL) declined from day 5 to day 20 in the presence of the HIV
proteins. After 20 days, Tat- treated MSC displayed a 21.4  4.5%
inhibition in population growth compared to controls, whereas Nef-
treated cells displayed a 10.6  3.0% inhibition (Fig. 1B). Moreover, we
observed an early cumulative effect of Tat+Nef with an inhibition of
proliferation of 35.5  0.4% after 20 days. Reduced proliferation was
confirmed by a decreased number of proliferative cells labelled with
BrdU at day 10 and day 20 (Fig. 1C,D). Apoptosis was not increased,
when assayed by caspase 3/7 activity (Fig. 1E).
In control cells, the percentage of senescent cells X-gal stained was
8.6  2.2% and 9.3  2.2%, after 10 and 20 days of culture,
respectively (Fig. 1F,G). After 10 days, senescence was increased in cells
treated with Tat+Nef, and after 20 days, its level was of 17.1  1.6%,
18.0  4.1% and 20.2  3.7% in Tat-, Nef- and Tat+Nef-treated cells,
respectively (Fig. 1F). Accordingly, the HIV proteins increased lysosome
accumulation, a hallmark of aging, after 20 but not 10 days (Fig. 1H).
Finally, we also found an increased protein expression of the cell cycle
arrest marker p21WAF1 after 10 and 20 days of treatment (Fig. 1I). Taken
as a whole, these results show that Tat- or Nef- treated cells presented
an increased onset on cell senescence after 20 days. Moreover, Tat+Nef
induced an early onset of senescence.
To confirm the specificity of the effect of Tat and/or Nef, we
performed experiments in the presence of mutated proteins Tat*Mut,
mutated in the transactivation domain, and Nef*Mut, a signalling-
defective mutant (Fig. S1). Tat*Mut displayed little effect on population
growth (Fig. S1A,B), senescence (Fig. S1D) and Lysotracker (Fig. S1E), as
compared to controls. Nef*Mut had no effect on cell proliferation (Fig.
S1 A–C), cellular senescence (Fig.S1D) or Lysotracker (Fig.S1E) in contrast
to nonmutated Nef.
We also treated the MSCs up to day 20 with the viral proteins and
then removed, or not, these proteins to evaluate the potential reversion
of the alterations (Fig. S2). As shown in Figures S2 A and B (Supporting
information), the removal of Tat and/or Nef was associated with a rapid
recovery of population growth, which results from a significant
attenuation in senescent cell generation (Fig. S2C,D), at day 30. These
results suggest the direct involvement of Tat and Nef in the observed
alterations.
Long-term treatment with Tat and/or Nef induces oxidative
stress and mitochondrial dysfunction
The production of reactive oxygen species (ROS), measured by CM-
H2-DCFDA oxidation and the reduction of nitroBlue tetrazolium (NBT),
which measures the cellular oxidase activity, was unchanged after
10 days of treatment with the HIV proteins, but increased after
20 days by 1.3- to 1.4-fold by Tat and/or Nef, when compared to
control cells (Fig. 2A,B) along with an increased superoxide dismutase
activity (SOD) (Fig. 2C). To search for mitochondrial dysfunction, we
evaluated mitochondrial volume by using Mitotracker Red labelling of
mitochondria. We observed that the volume of mitochondria on day
10 was mildly increased in Tat and/or Nef-treated MSCs and reached
up to 1.5-fold of control on day 20 (Fig. 2D). We observed a
destabilization of the mitochondrial membrane potential, as shown
by the JC1 test (Fig. 2E), with a 20% decrease in JC-1 fluorescence
in Tat- or Nef-treated cells, and a 30% decrease in Tat+Nef treated
cells after 20 days, in accordance with the onset of mitochondrial
dysfunction.
Tat*Mut and Nef*Mut displayed no effect on oxidative stress or
mitochondrial dysfunctions (Fig. S1F–H) at both day 10 and day 20. The
removal of the HIV proteins at day 20 was associated with the
normalization of oxidative stress and mitochondrial dysfunctions at day
30 (Fig. S2E–G). Thus, these complementary experiments confirm that
Tat and Nef have a direct impact on oxidative stress and mitochondrial
dysfunctions in MSCs.
An antioxidant treatment prevents Tat- and/or Nef-induced
oxidative stress
To assess whether ROS production was involved in the onset of cellular
senescence, MSCs were treated from day 10 to day 20 with the
antioxidant N-acetyl cysteine (NAC). As shown in Fig. 3A,B, on day 20,
NAC prevented increased ROS production induced by Tat and/or Nef.
NAC also normalized altered mitochondrial volume and function induced
by Tat but not by Nef (Fig. 3C,D). Regarding senescence, NAC mildly
prevented Tat-decreased proliferation and lysosome accumulation, but
did not change SA-b-galactosidase activity (Fig. 3E–G). This suggests
that even if oxidative stress participates to Tat-related dysfunction, its
role in the induction of Tat-related senescence is mild if any. In parallel,
NAC did not prevent Nef-induced decrease in cell proliferation, lysosome
accumulation and SA-b-galactosidase activity (Fig. 3E–G). Overall, these
results show that oxidative stress participated to Tat- but not to Nef-
related mitochondrial dysfunction and not, or mildly, to Tat- or Nef-
induced senescence.
Tat but not Nef induces inflammation: reversion of Tat effects
by the NF-jB inhibitor parthenolide
Treatment with Tat but not Nef resulted in an increased nuclear
translocation of the activated pro- inflammatory and pro-senescent
transcription factor NF-jB, as shown by the accumulation of the
activated phospho-Ser 536 form of p-65 in the nucleus (Fig. 4A). In
agreement, Tat- but not Nef- treated MSCs displayed an inflammatory
phenotype, as shown by the increased secretion of IL-6 and IL-8 (Fig. 4B,
C) observed after 10 days and persistent at 20 days.
To evaluate whether in Tat-treated cells, the early activation of NF-jB
and inflammatory markers could be responsible for the onset of cellular
senescence, we used parthenolide, an NF-jB inhibitor, over a short
period of time (48 h) on MSCs treated for 18 days with Tat or Tat+Nef.
As expected, treatment with the NF-jB inhibitor was able to prevent the
increased secretion of IL-6 and IL-8 (Fig. 4D,E) induced by Tat and
Tat+Nef. Regarding senescence, parthenolide significantly reduced the
inhibition of cell population proliferation induced by Tat (from
21.4  3.2% to 16.7  1.1%) and Tat+Nef (from 34.2  3.9% to
28.9  1.6%) (Fig. 4F) and normalized the percentage of senescent
cells in Tat- and Tat+Nef-treated cells to about 15% (Fig. 4G) and
lysosome accumulation (Fig. 4H). Moreover, parthenolide prevented
ROS production (Fig. 4I) and mitochondrial dysfunction in Tat- and
Tat+Nef-treated MSCs (Fig. 4J,K). Taken as a whole, these results
showed that Tat exerted its effect via the activation of NF-jB, which
induced the secretion of cytokines/chemokines leading to cellular
senescence and oxidative stress.
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Nef but not Tat decreases autophagy: prevention of Nef-
induced effects by rapamycin
After 20 days of treatment, Nef- but not Tat-treated cells showed a
decreased LC3II labelling of the autophagosomes of about 25% as
compared to the control (Fig. 5A,B). In accordance, we observed in Nef-
but not in Tat-treated cells a decreased conversion of LC3I to LC3II
reflecting a decrease in autophagic efflux from day 10 (Fig. 5C), and the
accumulation of the p62 protein (Fig. 5D), a marker of autophagy
inhibition. In addition, Nef decreased themRNA expression of autophagy-
inducing proteins such as ULK1, BECN1 and GABARAP (Fig. S3A).
Moreover, we observed a direct interaction between Nef (His-tagged)
and Beclin-1, which were co- immunoprecipitated (Fig. 5E), suggesting
thatNef could inhibit autophagy throughadirect interactionwithBeclin-1.
We also highlighted that Nef-induced decrease in autophagy
occurred together with a hyperactivation on day 10 and day 20 of
protein kinase B (Akt/PKB) (Fig. S3B), a kinase acting upstream of mTOR,
implicated in the inhibition of autophagy in response to IGF1 (Nair & Ren,
2012).
To evaluate whether Nef-induced inhibition of autophagy was a
primary event leading to senescence, we used rapamycin, an immuno-
suppressant that acts through the inhibition of mTOR, thus activating
autophagy (Markaki & Tavernarakis, 2013). When rapamycin was added
to MSCs from day 15 to day 20 of treatment with Nef and Tat+Nef, we
observed a decrease in MSC population growth, as expected owing to
the known antiproliferative activity of rapamycin (Fig. S3C). Despite this
effect, rapamycin treatment increased the amount of the autophagy
marker LC3II (Fig. 5F) and restored the LC3I to LC3II conversion
(Fig. 5G). Rapamycin decreased the level of senescence as shown by
the reduced percentage of senescent cells in control and Nef-treated
MSCs by 25% (Fig. 5H) and the reduced volume of lysosomes by about
45% for Nef and 52% for Tat+Nef (Fig. 5I). Rapamycin also decreased
the ROS production induced by Nef and Tat+Nef by 74% and 77%
(Fig. 5J) and mitochondrial content by 33% and 49% (Fig. S3D), and
increased the mitochondrial membrane potential (Fig. S3E). These results
showed that Nef inhibited autophagy, possibly in part through a direct
interaction with Beclin-1, leading to the onset of cellular senescence and
oxidative stress.
Long-term treatment with Tat and/or Nef alters MSC
osteoblastic differentiation
Age-related loss of bone mass is associated with altered differentiation
capacities affecting osteoblastic fate. Thus, we undertook a study to
evaluate the impact of Tat and/or Nef on the ability of MSCs to
differentiate into mature osteoblasts. After a 20-day pretreatment with
Tat and/or Nef, confluent cells were induced to differentiate in a pro-
osteoblastic media, in the presence of the HIV proteins. After 15 days of
differentiation, a decreased staining with alizarin red, which visualizes
calcium deposition, was observed in MSCs long-term treated with Tat
and/or Nef (Fig. 6A,B). Accordingly, the decreased ability of MSCs to
undergo osteoblastic differentiation in the presence of the HIV proteins
was supported by the lower level of the RUNX2 protein (Fig. 6C),
decreased RUNX2 mRNA expression (Fig. 6D) and also a decreased level
of osteocalcin secretion (Fig. 6E).
Discussion
We show here that the HIV proteins Tat and Nef can induce cellular
senescence and oxidative stress in BM-MSCs, leading to a reduced
capacity of differentiation towards the osteoblastic lineage. Importantly,
for the first time, we demonstrate that Tat-induced senescence was
mediated by the activation of the NF-jB pathway, while Nef-induced
senescence resulted from the inhibition of autophagy. We propose that
Tat and Nef, at low concentrations, could alter the osteoblastic
precursors, namely MSCs, giving new insights into the decreased BMD
observed in HIV-infected patients.
We evaluated here the impact of the HIV proteins Tat and Nef, as
both are known to be secreted by infected cells into the extracellular
media and suspected to induce bystander cellular damage to the
noninfected surroundings cells (Kyei et al., 2009; Raymond et al., 2011;
Debaisieux et al., 2012). Indeed, within the BM, MSCs could be the
indirect target of HIV infection.
We observed, at first, that both Tat and Nef induced cellular
senescence. Moreover, Tat and Nef cotreatment had a cumulative effect
related to the different signalling pathways affected by Tat and Nef.
Decreased population growth was a sensitive marker as it can be
observed as soon as after 5 days of treatment, while increased
senescence occurred only after 10 days when Tat and Nef were added
together, or 20 days for SA-b-galactosidase activity induced by Tat or
Nef alone and for lysosome accumulation.
Many studies have shown that oxidative stress plays a major role in
MSC alterations (Stolzing et al., 2008; Kasper et al., 2009; Brandl et al.,
2011). We observed that increased ROS production occurred latter that
the decreased cell proliferation, in response to the HIV proteins. The anti
oxidant molecule NAC reduced ROS production in both Tat- and Nef-
treated MSCs as expected; however, it could not prevent any of the
other effects induced by Nef alone. Therefore, we propose that Nef-
induced oxidative stress is a late event induced by senescence or is
induced independently of senescence. Otherwise, NAC prevented the
effect of Tat on mitochondrial dysfunction, but had a mild effect, if any,
on population growth and the level of lysosomes, indicating that the
ability of Tat to induce senescence is mainly not dependant upon
oxidative stress.
When evaluating the mechanisms whereby Tat altered MSCs, we
observed that cytokine secretion and NF-jB activation were affected
after 10 days, in accordance with the literature, indicating that Tat
mediates part of its effect through the activation of NF-jB (Mahieux
et al., 2001; Zhang et al., 2011). A common feature of aging tissues is
low-level chronic inflammation, termed inflammaging. The transcription
Fig. 4 Tat but not Nef induces a pro-inflammatory profile: reversion by the NF-jB inhibitor parthenolide. Representative immunoblots of nuclear phospho-p65-NF-jB
(ser536) and PCNA/proliferating cell nuclear antigen (loading control) at day 20 (A) are shown. Upon day 10 and day 20, the levels of IL-6 (B) and IL-8 (C) in the cell culture
media were determined with ELISA assays. Parthenolide (Part) was added, or not, at day 18 for 48 h. IL-6 (D) and IL-8 (E) in the cell culture media were determined. Results
are expressed as ng/mg of total cell proteins 24 h. Mean cell number and the per cent inhibition of population growth were calculated for each condition (F). Senescence
was evaluated by SA-b-galactosidase activity and expressed as the total per cent of SA-b-galactosidase cells at pH6 (G). Lysosomal accumulation was assessed by LysoTracker
fluorescence probe and expressed as per cent of control cells (H). ROS production was assessed on day 20 by the oxidation of CM-H2DCFDA (I). Mitochondrial mass was
evaluated by MitoTracker Red-Probe (J), and mitochondrial membrane potential by JC-1 fluorescent dye (K). Results are mean  SEM. All experiments were performed in
duplicate or triplicate. *P < 0.05, **P < 0.01,***P < 0.001, vs control or vs Tat- and/or Nef-treated cells without parthenolide. NS, nonsignificant.
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factor NF-jB has been shown to play a role in the induction of
senescence (Tilstra et al., 2011). In accordance, senescent cells secrete
proinflammatory cytokines and chemokines (such as IL-8 and IL-6)
representative of a senescence-associated secretory phenotype (Coppe
et al., 2008). NF-jB has been implicated in apoptosis, cell cycle
progression, cell senescence and inflammation (Tilstra et al., 2011;
Tchkonia et al., 2013). To assess its implication, we used parthenolide, a
selective inhibitor of the IjB kinase, resulting in stabilization of the
Fig. 5 Nef impedes the autophagic efflux in MSCs: prevention by rapamycin. MSCs were treated with the HIV proteins Tat and Nef for up to 20 days. The level of
autophagic activity was determined by LC3-II staining of autophagic vesicles, as stated in Experimental procedures. Total fluorescence of LC3-II was evaluated, and results are
expressed as per cent of control cells (409 magnification) (A). Representative micrographs of LC3-II-labelled and DAPI-stained cells are shown (1009 magnification) (B).
Whole-cell lysates were extracted from MSCs at day 10 and day 20 of treatment with the HIV proteins and analysed by immunoblotting. Representative immunoblots of LC3
and tubulin (loading control) and the relative quantification of LC3II/I ratio are shown (C). Representative immunoblots of p62 and tubulin (loading control) are shown (D).
Whole- cell lysates were extracted from MSCs at day 20 of treatment with histidine-tagged Nef, and Beclin-1 was immunoprecipitated. Representative immunoblots of Nef
(using an anti-his-tag antibody) and beclin-1 are shown (E). Rapamycin (Rapa) was added from day 15 to day 20. The level of autophagic activity was determined by with
LC3-II staining of autophagic vesicles, as stated in Experimental procedures. Total fluorescence of LC3-II was evaluated and results are expressed as % of control cells (F).
Representative immunoblots of LC3 and tubulin (loading control) and the relative quantification of LC3II/I ratio are shown (G). Senescence was evaluated by SA-b-
galactosidase activity and expressed as the total percentage of SA-b-galactosidase cells at pH6 (H). Lysosomal accumulation was assessed by LysoTracker fluorescence probe
and expressed as percentage of control cells (I). ROS production was assessed on day 20 by the oxidation of CM-H2DCFDA (J). Results are mean  SEM. All experiments were
performed in duplicate or triplicate. *P < 0.05, **P < 0.01,***P < 0.001, vs control or vs Tat- and/or Nef-treated cells without rapamycin. NS, nonsignificant.
(A) (B) (C)
(D)
(E)
Fig. 6 Tat- and Nef-induced senescence is associated with altered osteoblastic potential of MSCs. MSCs were differentiated into osteoblasts after 20 days of treatment with
Tat and/or Nef. To evaluate the osteoblastic potential of MSCs, cells were stained with Alizarin Red 15 days post induction of differentiation. Quantification of Alizarin Red is
expressed as per cent of control cells (A), and representative micrographs are shown (B). Whole-cell lysates were extracted at day 15 post induction of differentiation from
MSCs and analysed by immunoblotting. Representative immunoblots of RUNX2 and ERK1/2 are shown (C). Human RUNX2 and OSX mRNA levels were measured using real
time RT–PCR. The relative mRNA expression levels were normalized to PPIA (D). Osteocalcin in the cell culture media was determined with ELISA assays. Results are expressed
as pg/mg of total cell proteins-24 h (E). Results are mean  SEM. All experiments were performed in duplicate or triplicate. *P < 0.05, **P < 0.01,***P < 0.001, vs control
cells.
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cytoplasmic IjBa, which in turn leads to inhibition of NF-jB nuclear
translocation (Saadane et al., 2007). We found that all the effects of Tat
were prevented by parthenolide, which allowed us to establish
that NF-jB activation is a primary event in Tat-induced premature
senescence.
Regarding Nef, previous studies have shown that Nef can inhibit
autophagy through a direct interaction with Beclin-1, a protein required
for the nucleation of the autophagosome (Kyei et al., 2009; Killian,
2012). Autophagy is the central degradation process in cells required for
the recycling of damaged organelles and macromolecules (Rubinsztein
et al., 2011). We confirmed here that Nef, but not Tat, could inhibit
autophagy by using several markers including LC3I to LC3II conversion,
mRNA expression of specific markers of autophagy initiation (ULK1) and
autophagosome formation (Beclin1, GABARAP), accumulation of the
protein p62 and an autophagic adaptor and reveal a direct interaction
between Nef and Beclin-1. We also show that Nef could induce the
activation of Akt, which activates mTOR leading to autophagy inhibition.
Rapamycin, an activator of autophagy (Markaki & Tavernarakis, 2013),
was able to prevent the effect of Nef on both oxidative stress and cellular
senescence. Moreover, as Nef inhibits autophagy, it can also affect
mitophagy, inducing dysfunctional mitochondria accumulation (Dinkins
et al., 2010). This was also prevented in our study by the addition of
rapamycin. Altogether, these results suggested that inhibition of
autophagy could be the primary event in Nef-induced senescence.
Senescent MSCs are present in human BM of aged patients,
presenting increased oxidative stress and decreased cell plasticity,
affecting more particularly the osteoblast differentiation (Zhou et al.,
2008). Thus, we evaluated the impact of Tat and/or Nef on the ability of
MSCs to differentiate into mature osteoblasts. Early senescence, induced
by Tat and Nef, was associated with a loss of the ability of MSCs to
differentiate into osteoblasts, as shown by the decrease in several
osteoblastic markers and calcium deposition. These results are in keeping
with clinical data, showing a decreased BMD in HIV-infected patients
(Powderly, 2002; Brown & Qaqish, 2006; Stone et al., 2010), stressing
for a direct role of HIV in decreased bone formation.
Our study has limitations. It may not account for many factors
involved in the accelerated pro- osteoporotic process observed in HIV-
infected patients, meaning the HIV infection itself, immune balance,
environmental factors and genetic predispositions, together with ART.
As cellular senescence is a common pathway of many cell lineages other
than MSCs, it is possible that Tat and Nef could induce senescence of
several other cell types, as hematopoietic stem cells. The impact of Tat
and Nef on osteoclasts, derived from the hematopoietic lineage, remains
to be evaluated, as several studies indicate an increased level of
resorption markers in HIV-infected patients (Barkhordarian et al., 2011;
Haskelberg et al., 2011), emphasizing the role of HIV infection on bone
destruction. Our data suggest that some HIV proteins could induce
premature senescence of MSCs, therefore precluding the regeneration
process normally associated with bone loss. However, we have not
tested other HIV-1 proteins, which could also exert deleterious effects.
In conclusion, our data provide the first experimental support that HIV
proteins could induce senescence of MSCs. It has been suggested that
the regenerative capacity of tissues with high cell turnover, such as bone,
might be reduced due to exhaustion of progenitor cells. We hypothesize
that during HIV infection, induction of premature aging in MSCs, along
with chronic inflammation and continuous oxidative stress, could
contribute to cell attrition and MSCs exhaustion. Therefore, the
consequence of early senescence induced by HIV would be the lack of
an appropriate number of stem cells for further tissue replacement and
the development of bone loss and aging. While Nef inhibited autophagy,
we showed that Tat induced an inflammatory phenotype in MSCs, the
two proteins exhibiting cumulative effects. Thus, our results support the
idea that HIV-induced premature aging in MSCs, along with chronic
inflammation, autophagy inhibition and sustained oxidative stress, could
contribute to MSC exhaustion.
Experimental procedures
Cell culture and treatment
Experimental procedures, with human BM, have been approved by the
Saint Louis Hospital Ethical Committees for human research (Paris,
France), in accordance with the European Union guidelines and the
Declaration of Helsinki. MSCs were isolated from washed filters used
during BM graft processing. Healthy donors BM cells obtained after
Ficoll separation (Invitrogen Corporation, San Diego, CA, USA) were
cultured at the initial density of 5.104 cells/cm2 in alpha-minimum
essential medium, supplemented with 10% foetal bovine serum (Gibco,
Invitrogen Corporation), 2 mmol/L glutamine, 2.5 ng/mL bFGF (Pepro-
Tech, Rocky Hill, NJ, USA) and Penicillin/Streptomycin (Gibco, Invitrogen
Corporation) (Hernandez-Vallejo et al., 2013). Adherent cells were then
trypsinized, harvested and cultured by seeding 5.103 cells/cm2. Cultures
were fed every 2 to 3 days and trypsinized every 5 days. BM-MSCs
used in our study did not express hematopoietic antigens, such as CD34
and CD45, and were positive for CD73, CD44 and CD105 expression
(Larghero et al., 2008; Freida et al., 2013). All experiments were
performed on MSCs isolated from at least three different BM donors.
Cells were exposed to HIV recombinant proteins Tat (Diatheva, Fano,
Italy), His- tagged Nef (Jena Bioscience GmbH, Jena, Germany),
mutated Tat Cys22 (Diatheva, Fano, Italy) or signalling-defective mutant
Nef (Jena Bioscience GmbH, Jena, Germany) at the clinically relevant
concentrations observed in HIV-infected patients naive of treatment of
40 ng/mL (Gougeon, 2003; Boya et al., 2004; Raymond et al., 2011),
or to the solvent (PBS) for up to 30 days, from passage 3 to 8. Medium
was changed every 2 to 3 days. In some experiments, the cells were
also incubated for 10 days with 250 lmol/L N-acetyl-cysteine (NAC), or
for 5 days with 100 nmol/L Rapamycin (Rapa) or for 2 days with
100 lmol/L parthenolide (Part) (all from Sigma-Aldrich, St Louis, MO,
USA).
Cell proliferation and apoptosis
Cellular senescence was evaluated by the PDL value calculated as log2
(D5/D0), where D0 and D5 are the number of cells at seeding and
harvesting, respectively (Hernandez-Vallejo et al., 2013). Dividing cells
were identified by measuring bromodeoxyuridine (BrdU) incorporation
(BD Biosciences Pharmingen, San Diego, CA, USA). Upon day 9 and day
19 post-HIV-protein treatment, cells were incubated for 24 h with BrdU
(15 lmol/L), then fixed and permeabilized. Anti-BrdU antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was revealed using second-
ary antibodies coupled to Texas Red (Jackson ImmunoResearch Labo-
ratories, West Grove, PA, USA). Cell nuclei were visualized after
diamidino-phenylindole hydrochloride staining (DAPI, Sigma-Aldrich).
Dividing cells, examined by fluorescence microscopy, were counted in
four randomly selected fields and expressed as a percentage of total
cells. The percentage of apoptotic cells was determined using Apo-ONE
homogeneous Caspase-3/7 assay (Promega Biosciences, San Luis
Obispo, CA, USA). Quantification was performed on a plate fluores-
cence reader (Spectrafluor Plus, Tecan-France, Trappes, France) at
530 nm.
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Cellular senescence and autophagy
The positive blue staining of b-galactosidase was used as a biomarker of
cellular senescence. Cells were incubatedwith appropriate buffer solution
containing X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside)
(Sigma-Aldrich) (Hernandez-Vallejo et al., 2013). The blue-stained cells
observed at pH 6 and pH 4 were counted in eight fields at 209
magnification, and thepercentageof pH6positiveblue senescent cellswas
calculated. We used the acidotropic dye LysoTracker (Invitrogen Corpo-
ration) to evaluate lysosomal mass. Cells were cultured in 96-well plates,
washed and incubatedwith Lysotracker (50 nmol/L) in DMEM, for 30 min
at 37 °C in thedark.Quantificationwas performedonaplate fluorescence
reader (Spectrafluor Plus) at 620 nm. Autophagosomes density was
visualized by immunofluorescencewith an antibody directed against LC3II
(LC3, M152-3, MBL international, Woburn MA, USA) in MSCs cultured
with theHIVproteins for 20 days (Leica TCSSPmicroscope, 409and1009
magnifications). Nuclear DNA was stained with DAPI.
Cytokine/chemokine and osteocalcin secretion
Human IL-6 and IL-8 concentrations in cell culturemedia were determined
after 10 and 20 days of incubation with Tat and/or Nef, using Quantikine
human sandwich ELISA kits (R&D Systems, Inc. Minneapolis, MN, USA).
The sensitivity of the assays was: 0.7 pg/mL for IL-6 and 7.5 pg/mL for IL-
8. Human osteocalcin concentration in cell culture media from differen-
tiated MSCs was determined after 15 days of differentiation, by using
Osteocalcin Human Direct ELISA Kit (Life technologies, Gaithersburg, MD,
USA). The sensitivity of the assays was 0.4 ng/mL.
Osteoblast differentiation
Differentiation into osteoblasts was triggered on MSCs in the presence
of the HIV proteins, by culture in the osteoblast differentiation media for
15 days (10 mmol/L b-glycerophosphate, 50 lg/mL ascorbate). Cells
were then stained for Alizarin Red (Sigma-Aldrich) (Hernandez-Vallejo
et al., 2013).
Mitochondrial dysfunctions and oxidative stress
The cationic dye JC-1 (tetrachloro-tetra-ethyl- benzimidazolyl-carbocya-
nine iodide) evaluated the mitochondrial membrane potential, and the
MitoTracker Red probe (both from Invitrogen Corporation,) measured
mitochondrial mass. Cells, cultured in 96-well plates, were incubated
with JC-1 (4 lg/mL), or Mitotracker (50 nmol/L) in DMEM, for 60 min at
37 °C in the dark. Quantification was performed on a plate fluorescence
reader (Spectrafluor Plus, Tecan-France, Trappes, France) at 595 and
530 nm (JC-1 aggregates and monomers, respectively) or 630 nm
(MitoTracker). The production of ROS was assessed by the oxidation of
5-6-chloromethyl-2,7-dichlorodihydro-fluorescein diacetate (CM-
H2DCFDA) (Invitrogen Corporation) or the reduction of nitroblue
tetrazolium (NBT) (Sigma-Aldrich) (Hernandez-Vallejo et al., 2013).
Results were normalized to cell protein content. Superoxide dismutase
(SOD) activity was evaluated using a commercially available kit (Sigma-
Aldrich).
Protein extraction, immunoprecipitation and Western
blotting
Whole-cell protein and nuclear protein were extracted and then
electro-blotted on nitrocellulose membrane (Amersham Biosciences GE
Healthcare Europe, Velizy Villacoublay, France). Specific proteins were
detected by incubation with the appropriate primary antibodies
(p21WAF1, Phospho p65 subunit of NF-jB (ser 536), p62, Akt,
Phospho-Akt, RUNX2/CBFA, ERK1/2, PCNA) and horseradish-peroxidase-
conjugated secondary antibodies. Immune complexes were detected by
enhanced chemiluminescence (Amersham Biosciences GE Healthcare
Europe, Velizy Villacoublay, France). Co-immunoprecipitation was per-
formed on whole cellular extracts prepared in lysis buffer (Epitomics,
Burlingame, CA, USA) using Beclin-1 specific antibody (Abcam, Cam-
bridge, MA, USA) and Rabbit IgG-Dynabeads (Invitrogen Corporation).
All washing steps were performed using a Dynamagnet, and the elution
of Beclin-1 with its binding partners was performed by adding Laemmli
buffer and boiling. Western blot was then performed using a His-tag
specific antibody.
RNA isolation and quantitative RT–PCR
Total RNA was isolated from cultured cells using an RNeasy kit (Qiagen,
Valencia, CA, USA), and mRNA expression was analysed by RT–PCR
(Hernandez-Vallejo et al., 2013). The sequence of the oligonucleotides
used as primers is available upon request.
Statistical analysis
All experiments were performed at least three times on triplicate
samples. Data are expressed as means  SEM. Statistical significance,
between HIV-protein-treated cells vs control with or without partheno-
lide, rapamycin or NAC, was determined with nonparametric Wilcoxon’s
test.
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Fig. S1 Complementary results: Effect of Mutated Tat and Nef. MSCs were
treated with the nonmutated proteins Tat and/or Nef, Tat*Mut or Nef*Mut,
up to 20 days. Mean PDL values ( SEM), were determined at the indicated
days post-HIV-proteins treatment (A). The % inhibition of population
growth was calculated for each HIV protein compared to control cells (B).
BrdU incorporation was analysed by immunofluorescence microscopy to
determine the number of dividing cells after a 20-day treatment with HIV-
proteins mutated or not (C). SA-b-galactosidase activity was evaluated and
expressed as the total % of positive cells at pH6 (D). Lysosomal
accumulation was assessed by LysoTracker fluorescence probe and
expressed as % of control cells (E). ROS production was assessed by the
oxidation of CM-H2DCFDA (F) and expressed as % of control cells.
Mitochondrial mass was evaluated by MitoTracker Red-Probe (G), and
mitochondrial membrane potential by JC-1 fluorescent dye (H). Results are
mean  SEM. All experiments were performed in duplicate or triplicate in
MSCs isolated from 3 different bone marrow donors. *P < 0.05, **
P < 0.01,*** P < 0.001, vs control cells.
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Fig. S2 Complementary results: Impact at 30 days of the removal of Tat
and/or Nef after 20 days of treatment. MSCs were treated with the HIV
proteins Tat and/or Nef, either up to 30 days or up to 20 days and then the
proteins were removed up to day 30. Mean PDL values ( SEM), were
determined at the indicated days post-HIV-proteins treatment (A). The %
inhibition of population growth was calculated for each HIV protein at day-
30 compared to control cells (B). SA- b-galactosidase activity was evaluated
and expressed as the total % of positive cells at pH6 (C). Lysosomal
accumulation was assessed by LysoTracker fluorescence probe and
expressed as % of control cells (D). ROS production was assessed by the
oxidation of CM-H2DCFDA (E) and expressed as % of control cells.
Mitochondrial mass was evaluated by MitoTracker Red-Probe (F), and
mitochondrial membrane potential by JC-1 fluorescent dye (G). Results are
mean  SEM. All experiments were performed in duplicate or triplicate in
MSCs isolated from 3 different bone marrow donors. * P < 0.05, **
P < 0.01,*** P < 0.001, vs control cells.
Fig. S3 Complementary results: Nef impedes the autophagic efflux in MSCs:
prevention by rapamycin. Human BECN1, GABARAP and ULK mRNA levels
were measured using real time RT PCR on day-20 post HIV proteins
treatment. The relative mRNA expression levels were normalized to PPIA (A).
Whole-cell lysates were extracted from MSCs at day-10 and day-20 of
treatment with the HIV proteins Tat, Nef and Tat/Nef, and analysed by
immunoblotting. Representative immunoblots of Akt and Phospho Akt are
shown (B). Rapamycin (Rapa) was added from day 15 to day 20. Mean cell
number, and the per cent inhibition of population growth were calculated
for each condition (C). Mitochondrial mass was evaluated by MitoTracker
Red- Probe (D), and mitochondrial membrane potential by JC-1 fluorescent
dye (E). Results are mean  SEM. All experiments were performed in
duplicate or triplicate. * P < 0.05, ** P < 0.01,*** P < 0.001, vs control or
vs Tat- and/or Nef-treated cells without rapamycin. NS, non significant.
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